Endothelial cell activation by tumor necrosis factor elicits human antiporcine cell-mediated rejection responses.
Kirkiles-Smith
N C
NC
Yale University School of Medicine, New Haven, Connecticut, USA.
Tereb
D A
DA
Kim
R W
RW
McNiff
J M
JM
Schechner
J S
JS
Lorber
M I
MI
Pober
J S
JS
Tellides
G
G
D000328:Adult; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000187:drug effects / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D016513:Mice, SCID; D023421:Models, Animal; D016038:Skin Transplantation / Q000276:immunology; D013045:Species Specificity; D013552:Swine; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D018183:Transplantation Chimera / Q000276:immunology; D023001:Transplantation Tolerance / Q000276:immunology*; D014183:Transplantation, Heterologous; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology*
D016207:Cytokines; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D014409:Tumor Necrosis Factor-alpha